Table 2.
TXNIP regulatory signaling pathways.
Signaling pathways | Classification | Regulators |
---|---|---|
Common regulatory pathway | Transcriptional factors | MondoA[36], ChREBP [37], MLX [33], FoxO1 [37, 219], Max [220], KLF6 [221], STAT3 [39], NRF2 [222], NFATC2 [212], PAX5 [118], LKZF1 [118] |
microRNAs and circular RNAs | miR-21a [40], miR-148a [41], miR-135b-5p [42], miR-152-5p [43], miR-204 [24], miR-211 [223], miR-224 [224], miR-373 [225], miR-411-5p [226], miR-17 [55], miR-452 [213], miR-20a [213], miR-128-3p [132], miR-27a-3p [87], miR-424-5p [227], CircECE1 [120], circDCUN1D4 [228] | |
epigenetic regulators | EZH2 [44], UHRF1 [12] | |
regulators of mRNA and protein stability | LncRNA Gm15441 [45], LncRNA SNHG15 [46] | |
Oncogenes and TSGs | Oncogene | C-MYC [48], K-RAS [49], Ras [50], HER2 [51] |
Tumor suppressor | P53 [27], PTEN [28] | |
ER stress signaling | IRE-1a branch | IRE-1a [31, 54], XBP1 [56] |
PERK branch | PERK [57], ATF4 [229], CHOP [230] | |
Cytokines and Growth factors | Cytokines | TNFα [59], IL-1β [61], TGFβ1 [62] |
Growth factors | IGF1 [60] | |
Other regulatory conditions | Hypoxia condition | HIF-1a [65] |
mitochondrial labile iron dysfunction | CISD2 [68] | |
Drug treatment | All-trans retinoic acid [69] |